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A biologically active preparation of murine recombinant interleukin-lb (mIL-IS) from Escherichiu co/i cell lysates contained two forms of mlL-l/j 
with pI 8.7 and pI 8.1, respectively. Treatment with 0.1 M Tris, pH 8.5, at 37°C for 35 h converted the pX 8.7 form to the pl 8.1 form by the 
selective deamidation of an asparagine residue (Asn’49) in the mIL-IS molecule. Deamidated mIL-I/3 had 3- to 5-fold lower co-mitogenic activity 
and receptor affinity than the unmodified form. 
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1. INTRODUCTION 
IL-l’ mediates a range of biological activities in- 
cluding the activation of cells involved in immune and 
inflammatory responses [1,2]. The two molecular 
forms of mature (17 kDa) human IL-l, cy (~~1-5.0) and 
p (~1-7.0)~ are only about 25% homologous in se- 
quence but bind to the same receptor [3] and share 
elements of 3D structure [4-61. Although most atten- 
tion has centered on the human proteins, mlL-lu and 
mIL-lfl are valuable research reagents that have been 
produced by recombinant expression in E. coli [7-g]. 
This report describes a modification of the structure of 
mIL-l,& that was noted during its recovery from 
bacterial lysates and caused heterogeneity in the’ 
isolated recombinant product. The heterogeneity was 
due to selective deamidation of a single Asn residue, 
and the results are of interest both in terms of 
structure-activity relationships of IL-1j3 and with 
regard to the structural factors governing deamidation 
of amide residues in proteins. 
by centrifugation. The protein was dissolved in buffer (SO mM Tris, 
1 mM EDTA, 1 mM DTT, 1 mM NaN3, pH 7-O), desalted on a 
Sephadex G-25 column. and fractionated on a DE-S2 cellulose col- 
2. MATERIALS AND METHODS 
2.1. Protein purijicution 
mIL-la was precipitated from bacterial cell lysates with am- 
monium sulfate and recovered from the 2%80% saturated fraction 
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umn equilibrated in the same buffer. 
2.2. Analytical biochemical methods 
The procedures used for SDS-PAGE, IEF, cation exchange 
chromatography, molecular exclusion HPLC and amino acid 
analysis have been described [91. Protein sequencing was performed 
using an Applied Biosystems Model 470A gas-phase sequencer equip- 
ped with a Model 120A on-line PTH analyzer. Alternatively. PTH 
amino acids were identified in off-line mode using a Zorbax PTH col- 
umn (DuPont). Data were acquired, stored and analyzed using a PE 
Nelson data system. 
3. RESULTS 
3.1. Expression, purification and activity of ML-&3 
To obtain mlL-l&7, a semisynthetic gene encoding an 
initiator Met followed by the C-terminal 152 amino 
acids (residues 118-269) of the mlL-lb precursor [lo] 
was expressed in E. coli as lo-15% of the total cellular 
protein. The recombinant cytokine, which was re- 
covered exclusively from the soluble fraction of cell 
lysates, was isolated and purified by ammonium sulfate 
fractionation and anion exchange chromatography, 
The isolation procedure yielded a product which ap- 
peared homogeneous by SDS-PAGE (Fig. 1A) but was 
resolved by IEF into two protein species with pIs of 8.7 
and 8.1 (Fig. 1B). 
The two mlL-l@ species were isolated by cation ex- 
change chromatography (Fig. 1C) and each was analyz- 
ed separately. The proteins exhibited identical amino 
acid compositions and N-terminal ,sequences (10 
residues), each retaining the initiator methionine. They 
also had the same molar absorptivity (15 000 M-’ - cm-’ 
,at 280 nm). They had identical A4 as judged by 
molecular exclusion HPLC and SDS-PAGE, and both 
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Fig. 1. (A) SDS polyacrylamide gel electrophoresis howing isolation of recombinant mIL-I,&. Lane 1, total cell lysate; lane 2, soluble fraction 
of lysate; lane 3. 25-80% saturated ammonium sulfate fraction; lane 4, desalted pooled protein fraction; lane 5, DEAE-52 pooled fractions 
(0.49 cg loaded). (B) Isoelectric focussing of mIL-lfl after incubation in alkaline buffer. Lanes 1 and 4, mlL-l,@ before MonoS column; lane 2, 
first MonoS peak (~18.1) (see panel C); lane 3, second MonoS peak (pI 8.7); lane 5, IEF standards. (C) Cation exchange chromatography. mlL-I,@ 
high and low p1 species were isolated on a Pharmacia MonoS MR IO/10 cation exchange column using a NaCl gradient in 0.1 M NW.J-ICOZ. 
pH 5.3. 
proteins contained a cysteinyl residue which was 
detected with DTNB only after denaturation with 6 M 
&&ICI. 
In the thymocyte co-rnitogenic assay [ 111, the p1 8.1 
species was consistently less active than the pI 8.9 
species. The average specific activity from 6 determina- 
tions with 3 separate preparations of each form of the 
cytokine were 2.7 f 1.3 X 10” U/mg for the high p1 
. species and 0.6 & 0.13 x 10” U/mg for the low p1 form 
with a mean 5.2 f 1 .$-fold decrease in activity as deter- 
mined from 6 paired comparisons. The low p1 form 
also exhibited a 3-fold decrease in affinity for the IL-1 
receptor. In a competitive receptor binding assay with 
28 pM [‘2sI]hIL-la, [Ill the average effective concen- 
tration causing 50% displacement by the high and low 
p1 mIL-1P species were 133 f 14 pM and 356 -r- 50 pM, 
respectively. 
3.2. b=ormation of the less active form of mIL-48 
The ~18.7 protein (0.9 mg/ml) was converted to the 
less biologically active p1 g.1 species by incubation at 
37OC in 0.1 M Tris, pM 8.5. The rate of conveision was 
determined by cation exchange chromatography, and a 
reaction half-life of 35 h was calculated. IEF analysis 
of reaction mixture ,aliquots demonstrated the ap- 
pearance of a diffuse band at p1 8.1 with the concomi- 
tant disappearance of the p1 8.9 band. However, upon 
prolonged incubation, the intensity of this p1 8.1 band 
also decreased with the concomitant appearance: qf a 
third protein band at p1 9.0. 
While this observation tended to support the hypo- 
thesis that deamidation of Asn and/or Gln residue(s) 
caused the formation of the low p1 species, the alkaline 
conditions used in these experiments were too mild to 
effect indiscriminate protein deamidition [ 12-141. 
Selective deamidation of one or more residues appeared 
more plausible and the task of idtrbtifying the site(s) of 
deamidation was undertaken. 
3.3. Structural analysis of the less active form of, 
mlL-l# 
The primary structure of mIL-lfi includes 9 Asn and 
11 Gln residues (Fig. 2). The initial strategy followed to 
identify deamidation at any of these sites was to digest 
each protein with Staphylococcus clureus V8 protease. 
In phosphate buffer, S. aureus V8 protease cleaves pro- 
teins at the carboxyl side of both aspartyl and glutamyl 
residues’ [IS]. Therefore, digestion of ‘the two mIL-1,8 
species might have generated different peptide maps 
because deamidation would have produced new peptide 
cleavage sites. Comparison of the WPLG peptide maps 
(not shown) failed to reveal any difference between the 
two forms, but the peptides recoverid in this analysis 
accounted for only 57vo of the total protein. From 
these maps the first 13 N-terminal residues (residues 
118-130) and the last 73 C-terminal residues (residues 
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was not recovered from the I-IPLC experiment, and this 
portion contained 11 of the 20 amide residues in the 
118 121 125 128 147 149 
’ I ‘LA mIL-l/S VP I BHYR D EQkK SLMS DPY ELR$l !idIJiDQNINq~ VIFSMS~IEPS 
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hIL-1) NNk%J AQFPN @ QAUr& CTCOQ DITk%XVS S 
213 
Pig. 2. Amino acid sequence alignments of mature mlL-10 and 
hlL-1,B. Residues were numbered according to the respective 
precursor molecules. Portions of the hlL-14 sequence which are 
underlined below the amino acid residues correspond to the twelve ,8- 
strands (,Ol-,612) [S&l. Residues not underlined correspond to the 
connectors between the strands. Residues which upon substitution 
result in neutral mutations 121-241 are underlined by an asterisk (*). 
The initiator Met present in recombinant-derived mIL-l,B is not 
shown. 
193-269) were identified; since the maps were identical, 
selective deamidation of any Asn or Gln among these 
residues was ruled out. However, the portion of the 
protein (43%) encompassing residues 131-196 (Fig. 2) 
protein. 
As a direct analysis of this region of the protein, each 
pI form was subjected to an extended N-terminal se- 
quence analysis (continuous automated Edman 
degradation through 40 residues). These analyses show- 
ed that none of the nine amide residues within this 
region was deamidated in the high pl species, but that 
Asn’“’ was deamidated (cycle 33) in the low pI protein 
(Fig. 3). This was the only residue seen to be 
deamidated, but its deamidation was incomplete; in the 
sequence analysis of this step, Asp and Asn were 
detected in a 65 : 35 ratio (Fig. Sb). 
Isoelectric focusing of the low p1 preparation showed 
no evidence of contamination with the high p1 species. 
Thus, it appeared likely that the remaining 35% of pI 
8.1 molecules resulted from partial deamidation at 
another specific site or at multiple additional sites. The 
observation that a form with a pI less than 8.1 could be 
generated during the alkaline incubation (see above) 
supported the contention that limited deamidation oc- 
curred at additional sites. 
CNBr digestion followed by covalent chromatog- 
raphy on thiopropyl Sepharose (not shown) was used to 
isolate the Cys’** containing peptide encompassing 
residues 162-191; this peptide contained the three 
amide residues (Gln’6S, Asn17’ and Asn’53) unac- 
-10 




Fi3. 3. Changes in yields of PTH-Asn and PTH-Asp in cycles 30-X) of sequence arxdyses of (a) high and (5) low p! mIL-119, Yields are uncorrected 
for lag and background variations. 
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counted,for in the analysis. Sequencing of each Cys”’ small residue (especially Gly) immediately after Asn 
iontainihg fragment from b’&h high &d low p1 species [12,18~20]. 
failed to reveal any degmidation. mIL-1,8 and ML-l,& share 84% primary sequence 
Because of the’ critical nature of the experiment, the hdmology and their biological activities are in- 
extended N-terininal sequencing of the two PI, forms distinguishable. IBecause the ttio proteins are so similar 
was’ performed twice using’,different methods. On the in sequence and in function, ttieir tertiary structures are 
first occasion, PTI-I amino acids were analyzed using likely also to be closely’similar. The tertiary structure 
an off-line I-IPLC procedure based on an isocratic for mIL-l,@ has not been solved nor have site-directed 
separation. In the second experiment (Fig. 3), on-line mutagenesis studies been reported for the murine 
gradient hiPLC was employed. Data from the two ex- cytokine. However, the crystal structur&of hIL-lfi has 
periments were in full agreement, so that the assign- been refined to 2 A resolution [5,6], and several muta- 
ment of Asn’49 as the piimary site of deamidation was tions have been introduced into this molecule (Fig. 2), 
made with confidence. some of which negatively affect cytokine function. The 
point mutations shown to produce ML-lp rriolecules 
4. DISCUSSION 
with decreased biological activity correspond to 
substitutions at the following residues: Arg12’ [23], 
Deamidation of Asn or Gln residues in polypeptides Cyslz4 [21], Argl” 1241 and I-Iis146 !a%]. Upon sequence 
occurs through’ formation of a cyclic intermediate alignment of the ‘two prdieins, these residues corres- 
which is hydrolyzed to yield one of two possible pro- pond to Arg121, Tyr”‘, Arg128 and I-Iis147 in rhe murine 
ducts 1121. In the case of Asn residues, these products polypeptide (Fig. 2). In the hIL-I@ structure, CYS’~~ is
are (i) a normal peptide in which the native Asn ha? inaccessible to solvent whereas Arg12’ and Arg127 are 
been replaced by Asp or (ii) a pepride isomer in which exposed [5,6]. While these 3 residues are located within 
Asn has beeti replaced by an isoaspartyl residue [ 121. In the first &sheet of the hIL-I,& molecule, I-Iis’46 forms 
either case, a carboxyl group is present ibl the residue part bf the connecting loop between &sheets 3 and 4 
thar replaces the original nelitral Asn and the modified [5&l. Clearly, mpltaations- which affect binding to the 
protein has a lower p1 than the native protein. Sequence receptor, for example at I-Iis146, must affect biological 
and local c&formation are both factors iti governing activity because internalization of IL- lfl is required for 
the susceptibility of any individual Asn to deamidation expression of its activity [25,26]. Loss of cytokine func- 
[16]. tion, however, does not necessarily imply loss of recep- 
Automated Edman sequencing revealed that the ex- tor binding. In fact, receptor binding and biological 
ceptional lability to deamidation of bacterially express- activity have been uncoupled in an R127G hIL-1,d mu- 
ed mIL-lb was mainly due to the ease with which this tant protein 1241. This mutation results in a biologically 
modificaeiotd occurred at A&*“’ (residue 33 of rhe inactive molecule‘which essentially retains its ability to 
methionyl mature cytokine). The p1 8.1 form of Ihe bind to the.receptor [24]. Our results show that in- 
niolecule was at least 65% deamidated to Asp at this troduction of a negative charge at Asn”’ resulted in a 
position, while a further fraction of Asn”’ may have murine cytokine with significantly reduced receptor 
been converted ‘to an isoaspartyl residue which could binding affinity and rhymocyte co-tiifogenic activity. 
not have been detected by the methods applied. Edman The hdmologous residue to Asn149 in the human species 
seqluencing is arrested in chains where rhe latter event is Gin’“” which, like His146, is exposed to solvent and 
has occurred [47], so tha! the estim?te of 65 :35 forms part of the connector between ,&sheet,s 3 and 4 
distribution between Asp and Asn for residue i49 of [5,6]. This connecting loofi in hIL-IF includes thiee se- 
the p1 8.1 form ,does not take into account the possible quential type III &turns, forming a 3lo-helical structure 
presence of molecules in which Asn14’ has been con- encompassing residues G~Y”~ through Gly”” [S]. Based 
verted to isoaspartic acid. The fact that sequencing con- on ,our observations with mIL-1P deamidated at Asna49 
tinued ‘past the d&midation site without major loss of and observations of others on hIL-14 [21-241 we sug- 
yield is consistent with the interpretation that conver- gest th&, in addition to &sheet 1, the loop connecting 
sion to Asp was ,the principal product of the alkali- &strand 3 and p-strand 4 may be required to preserve 
induced chemical modification in the present case. This the biological activity of IL-l,& and that this loop could 
result -contrasted with that observed with human represllit an important site for receptor binding to the 
growth hormone in which isoaspartyl was by far cytokine. 
(70-80%) the mijor product of deamidation of an Asn 
residue [18]. 
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